Phase 2 GAN Clinical Trials
43 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 43 trials
Recruiting
Phase 2
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Gastric CancerOvarian CancerCholangiocarcinoma+7 more
National Cancer Institute (NCI)320 enrolled1 locationNCT06503146
Recruiting
Phase 2
Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)
Immune DysregulationPrimary Immune Regulatory DisorderChronic Granulomatous Disease+12 more
Paul Szabolcs25 enrolled1 locationNCT07284641
Recruiting
Phase 1Phase 2
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
ParagangliomaPheochromocytomaMeningioma+4 more
Perspective Therapeutics300 enrolled19 locationsNCT05636618
Recruiting
Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC322 enrolled84 locationsNCT04924075
Recruiting
Phase 2
A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease
GM2 GangliosidosisNiemann-Pick Type C Disease
Azafaros A.G.21 enrolled3 locationsNCT07399704
Recruiting
Phase 2Phase 3
Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
Radiotherapy Side EffectNeoadjuvant TherapyChemotherapy+8 more
National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos400 enrolled1 locationNCT06758830
Recruiting
Phase 2
Further MT for Antibiotic-Resistant Bacterial Colonization
Intestinal Multi-drug Resistant Organism Colonization
Emory University40 enrolled6 locationsNCT05835206
Recruiting
Phase 2
Chinese Adults With Kidney Disease
Immunoglobulin A Nephropathy (IgAN)IC-MPGNComplement 3 Glomerulopathy (C3G)
ADARx Pharmaceuticals, Inc.30 enrolled10 locationsNCT07522099
Recruiting
Phase 2
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
GerminomaBasal Ganglia GerminomaDiabetes Insipidus+3 more
Children's Oncology Group240 enrolled109 locationsNCT06368817
Recruiting
Phase 2
Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain
MigraineCluster HeadacheCraniofacial Pain+3 more
Stanford University15 enrolled1 locationNCT04930887
Recruiting
Phase 2
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Neuroendocrine TumorsParagangliomaPheochromocytoma+1 more
National Cancer Institute (NCI)130 enrolled1 locationNCT03206060
Recruiting
Phase 2
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
IgA Nephropathy (IgAN)IgANC3G+2 more
ADARx Pharmaceuticals, Inc.45 enrolled25 locationsNCT06989359
Recruiting
Phase 1Phase 2
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
ParagangliomaPheochromocytomaSolid Tumor Cancer+17 more
Fundación de investigación HM25 enrolled1 locationNCT06607692
Recruiting
Phase 2
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals32 enrolled8 locationsNCT07146906
Recruiting
Phase 1Phase 2
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
High Risk NeuroblastomaRefractory NeuroblastomaRelapsed Neuroblastoma+1 more
Beijing Biotech36 enrolled1 locationNCT07502287
Recruiting
Phase 2Phase 3
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Nationwide Children's Hospital500 enrolled32 locationsNCT05267821
Recruiting
Phase 1Phase 2
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
PheochromocytomaGastrointestinal Neuroendocrine TumorsSomatostatin Receptor Positive+1 more
National Cancer Institute (NCI)66 enrolled1 locationNCT06427798
Recruiting
Phase 2
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
COVID-19Inflammatory Bowel DiseaseRheumatoid Arthritis (RA)+5 more
McGill University Health Centre/Research Institute of the McGill University Health Centre660 enrolled3 locationsNCT06599658
Recruiting
Phase 2
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
Pyoderma GangrenosumWound HealSkin Diseases+2 more
Oregon Health and Science University17 enrolled2 locationsNCT06563323
Recruiting
Phase 2
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
Classic Hodgkin LymphomaAdvanced Hodgkin LymphomaLugano Classification Stage III Hodgkin Lymphoma AJCC v8+1 more
University of Washington125 enrolled5 locationsNCT06745076